Suppr超能文献

放疗对老年恶性神经胶质瘤患者的疗效

Efficacy of radiotherapy for malignant gliomas in elderly patients.

作者信息

Villà S, Viñolas N, Verger E, Yaya R, Martínez A, Gil M, Moreno V, Caral L, Graus F

机构信息

Service of Radiation Oncology, Institut Català d'Oncologia, L'Hospitalet, University of Barcelona, Spain.

出版信息

Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):977-80. doi: 10.1016/s0360-3016(98)00356-3.

Abstract

PURPOSE

Age above 65 years is a strong negative prognostic factor for survival in patients with malignant gliomas (MG) treated with radiotherapy (RT) and its value has been questioned. We analyzed the effect of RT on the survival of elderly patients with malignant gliomas.

METHODS AND MATERIALS

We examined 85 consecutive elderly patients with a histological diagnosis of MG. Age ranged from 65 to 81 years (median 70 years). Glioblastoma multiforme (GBM) was diagnosed in 64 patients (75.3%). Surgical treatment included needle biopsy in 32 patients (37.6%). Median postoperative Karnofsky Performance Status (KPS) was 60 (range: 30-100). Survival probability was estimated using Kaplan-Meier method and compared with the log-rank test. Crude and adjusted hazard ratios (HR) were calculated using Cox's regression models.

RESULTS

Median survival time for all patients was 18.1 weeks. In multivariate analysis, RT was the only independent prognostic variable for survival (HR: 9.1 [95% CI: 4.5-18.7]). Forty-two patients did not start RT mostly due to low KPS (<50). The median survival of the 43 patients who started RT was 45 weeks. In these patients, Cox multivariate analysis indicated that age was independently associated with prolonged survival (HR: 2.85 [95% CI 1.31-6.19]). Median survival of patients age 70 years and younger was 55 weeks compared with 34 weeks for patients older than 70 years.

CONCLUSIONS

The overall survival for elderly patients with MG is poor. RT seems to improve survival in patients up to 70 years, but in older patients treated with RT the survival is significantly shorter.

摘要

目的

65岁以上是接受放疗(RT)治疗的恶性胶质瘤(MG)患者生存的一个强有力的负性预后因素,其价值一直受到质疑。我们分析了放疗对老年恶性胶质瘤患者生存的影响。

方法和材料

我们检查了85例连续的经组织学诊断为MG的老年患者。年龄范围为65至81岁(中位年龄70岁)。64例患者(75.3%)诊断为多形性胶质母细胞瘤(GBM)。32例患者(37.6%)接受了手术穿刺活检。术后卡氏功能状态评分(KPS)中位数为60(范围:30 - 100)。采用Kaplan - Meier法估计生存概率,并通过对数秩检验进行比较。使用Cox回归模型计算粗风险比和调整风险比(HR)。

结果

所有患者的中位生存时间为18.1周。在多变量分析中,放疗是生存的唯一独立预后变量(HR:9.1 [95% CI:4.5 - 18.7])。42例患者未开始放疗,主要原因是KPS低(<50)。开始放疗的43例患者的中位生存期为45周。在这些患者中,Cox多变量分析表明年龄与生存期延长独立相关(HR:2.85 [95% CI 1.31 - 6.19])。70岁及以下患者的中位生存期为55周,而70岁以上患者为34周。

结论

老年MG患者的总体生存期较差。放疗似乎能改善70岁及以下患者的生存,但在接受放疗的老年患者中,生存期明显较短。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验